Biocon Ltd. (NSE: BIOCON) |
|
|
|
| Stock Quote |
| |
|
|
|
|
|
| Script Name |
BIOCON |
High |
352.7 |
EPS |
15.78 |
| |
|
|
|
|
|
| % Change |
-0.3 |
Low |
345.2 |
PE |
21.90 |
| |
|
|
|
|
|
| Open |
351.35 |
Volume |
162971.0 |
F PE |
69.10B |
| |
|
|
|
|
|
| Close |
347.3 |
Yield |
226.15 - 356.00 |
Beta |
- |
| |
|
|
|
|
|
| Last Traded Price |
346.25 |
Shares |
200.00M |
Dividend |
|
|
 |
|
|
| Ratios |
|
|
| Net profit margin
| 11.89%
| 12.59%
|
| Operating margin
| 14.33%
| 14.62%
|
| EBITD margin
| -
| 21.39%
|
| Return on average assets
| -
| 11.05%
|
| Return on average equity
| -
| 17.94%
|
| Employees
| 4,478
| -
|
| Carbon Disclosure Rating
| -
|
-
|
|
|
|
| BIOCON Company Summary |
| |
|
Biocon Limited (Biocon) is a global biopharmaceutical company with products and research services ranging from pre-clinical to clinical development through to commercialization. Within biopharmaceuticals, the Company manufactures generic active pharmaceutical ingredients (APIs) like Statins and Immunosuppressants that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar Insulins, which are sold in India as branded formulations and in both bulk and formulation forms. In research services, Syngene International Limited (Syngene) is engaged in the business of custom research in drug discovery while the other fully owned subsidiary Clinigene International Limited (Clinigene) is in the clinical development space. In December 2009, Biocon acquired the the Active Pharma Ingredients (API) undertaking from IDL Speciality Chemicals Ltd., a subsidiary of Gulf Oil Corporation Limited.
|
|
| Stock Holders |
| Name |
Client ID |
Qunatity |
Avg Buy Price |
Current Market Price |
P/L |
| kannan p |
248602 |
4004000000000 |
228 |
346.25 |
473473000407040.00 |
| Bhavin Chudasama |
135372 |
100000000 |
148 |
346.25 |
19825000448.00 |
| subodh singh |
122880 |
10000 |
223 |
346.25 |
1232500.00 |
| kashiff ali |
491040 |
6500 |
278 |
346.25 |
443625.00 |
| Rohan Uppal IMT |
190523 |
5000 |
101 |
346.25 |
1226250.00 |
| Investment Idea about BIOCON |
| Ashok Bansal |
Posted On:2010-08-14 07:12:19.0 |
| On the daily chart, Biocon has given an upside breakout in Thursday trading session. It suggests that the consolidation range is about to end and may reverse into an uptrend. On Thursday, the stock rallied by over 4% confirming the bullish set up. Moreover, the stock has given a close above its key moving averages on expanding volumes. The other supportive technical oscillators are positive and the up move may extend to the levels of Rs 355. IIFL is bullish on Biocon and has recommended buy rating on the stock with a target of Rs 355, in its August 13, 2010 research report. |
| Ravi Goyal |
Posted On:2010-05-02 18:56:15.0 |
| It is a good long-term bet. Some of its new launches in rheumatoid arthritis and cancer segments may provide stupendous growth for the company. Its FY11 earnings are estimated at 19 per share. Buy with a target price of 380 in 12 months. |
| shrek khan |
Posted On:2010-02-14 09:31:29.0 |
| The CMP of Rs 268 discounts the FY10E EPS of Rs 15.3 by 17.5x and FY11E EPS of Rs 18.2 by 14.7x. The company is likely to benefit from the growth in statins, recombinant insulin, contract research and formulations businesses. Biocon is the leading player in statins and exports over 80% of its production commands over 20% global market share and derives 30% of its revenues from this business. The company caters to regulated markets including US and Europe. The global patents of Lovastatin, Simvastatin and Pravastatin have already expired and they have become generic. The patent for Atorvastain is expiring in 2010 in UK and 2011 in Germany. This is likely to offer a huge opportunity due to its USD 12 billion market size. HDFC Securities is bullish on Biocon and has recommended buy rating on the stock with a target of Rs 327, in its February 11, 2010 research report. |
| Click here to see all Investment Ideas for BIOCON |
|
|
|
